New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
12:30 EDTPRGOPerrigo announces launch of betamethasone valerate foam 0.12%
Perrigo announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, , which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition. Betamethasone valerate foam 0.12% is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). Brand annual sales were approximately $40M as measured by Symphony Health.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:41 EDTPRGOPerrigo announces out-licensing of preclinical assets to Imago Pharmaceuticals
Subscribe for More Information
07:17 EDTPRGOLumara Health to be acquired in two separate transactions for $1.11B
Subscribe for More Information
07:11 EDTPRGOPerrigo acquires women's health product portfolio from Lumara for $82M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use